AV.TK-mediated killing of subcutaneous tumors in situ results in effective immunization against established secondary intracranial tumor deposits
- 1 September 2001
- journal article
- Published by Springer Nature in Gene Therapy
- Vol. 8 (17) , 1315-1322
- https://doi.org/10.1038/sj.gt.3301526
Abstract
At the forefront of medicine, Gene Therapy brings you the latest research into genetic and cell-based technologies to treat disease. It also publishes Progress & Prospects reviews and News and Commentary articles, which highlight the cutting edge of the field.Keywords
This publication has 41 references indexed in Scilit:
- Enhancement of the Herpes Simplex Virus Thymidine Kinase/Ganciclovir Bystander Effect and Its Antitumor Efficacy In Vivo by Pharmacologic Manipulation of Gap JunctionsHuman Gene Therapy, 1998
- Preclinical Testing of Recombinant Adenoviral Herpes Simplex Virus-Thymidine Kinase Gene Therapy for Central Nervous System MalignanciesNeurosurgery, 1997
- Intracranial Administration of Adenovirus Expressing HSV-TK in Combination with Ganciclovir Produces a Dose-Dependent, Self-Limiting Inflammatory ResponseHuman Gene Therapy, 1997
- The role of cytokines in mediating the bystander effect using HSV-TK xenogeneic cellsCancer Letters, 1995
- Adenovirus‐mediated gene therapy of experimental gliomasJournal of Neuroscience Research, 1994
- Vδ1+ Gamma/Delta T Lymphocytes Infiltrating Human Lung Cancer Express the CD8α/α HomodimerScandinavian Journal of Immunology, 1994
- The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in ratsJournal of Neurosurgery, 1994
- In VitroEvidence That Metabolic Cooperation Is Responsible for the Bystander Effect Observed with HSVtkRetroviral Gene TherapyHuman Gene Therapy, 1993
- Brain Tumor Treatment: Significant ContributionsScience, 1992
- Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5Journal of General Virology, 1977